secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2021-12-07T23:59:59+00:00
Accession:  0001564590-21-059570
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera appoints Andrew Lo as independent director; John Hamer resigns
------------------------------------------------------------------------

- Andrew W. Lo, Ph.D., appointed as independent director effective December 7, 2021.
- Lo will serve on Audit and Compensation Committees; he is an MIT professor and TIME 100 honoree.
- John Hamer, Ph.D., managing partner at DCVC Bio, resigned from the board effective immediately.
- Hamer had served on the board since 2018, including on Audit and Compensation Committees.
- CEO Carl Hansen thanked Hamer for his guidance and welcomed Lo for his financial/biomedical expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021059570/0001564590-21-059570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021059570/abcl-8k_20211207.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-059570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer